Patents Represented by Attorney Dianne Brown

Find this attorney in the Justia Lawyer Directory

  • Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
    Patent number: 7618994
    Abstract: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: November 17, 2009
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Carl Berthelette, Nicolas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Pyridopyrrolizine and pyridoindolizine derivatives
    Patent number: 7618979
    Abstract: Pyridopyrrolizine and pyridoindolizine derivatives are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.
    Type: Grant
    Filed: October 28, 2003
    Date of Patent: November 17, 2009
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Yves Leblanc, Claude Dufresne, Patrick Roy
  • Asymmetric hydrogenation process
    Patent number: 7576118
    Abstract: The present invention provides an asymmetric hydrogenation process for the preparation of chiral cycloalkanoindole DP receptor antagonists in high enantiomeric excess.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: August 18, 2009
    Assignee: Merck & Co., Inc.
    Inventors: David M. Tellers, Guy R. Humphrey
  • Tyrosine kinase inhibitors
    Patent number: 7186723
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: March 6, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer
  • Tyrosine kinase inhibitors
    Patent number: 7169788
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: January 30, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth L. Arrington, Mark E. Fraley, George D. Hartman
  • Tyrosine kinase inhibitors
    Patent number: 7125888
    Abstract: The present invention relates to imidazopyridine compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: October 24, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Zhicai Wu
  • Tyrosine kinase inhibitors
    Patent number: 7115597
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: October 3, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, Jr., John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Jr., Leonard Rodman
  • Tyrosine kinase inhibitors
    Patent number: 7109204
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: September 19, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, William F. Hoffman, George D. Hartman, Jennifer P. Peckham
  • Tyrosine kinase inhibitors
    Patent number: 7101884
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: September 5, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth L. Arrington, Mark E. Fraley, Barbara Hanney, Yuntae Kim, Keith L. Spencer
  • Blister package for pharmaceutical treatment card
    Patent number: 6978894
    Abstract: A blister package for a pharmaceutical treatment card suitable, the blister package having a plurality of individual blisters suitable for containing a pre-measured dosage of a pharmaceutical composition in the form of tablets, pills and capsules. In accordance with a pre-determined schedule of administration of the individually sealed blisters may be opened by a method of tearing, peeling and pushing. The blister card package can be characterized as a multiple layer laminate assembly having a plurality of transparent cavities containing composition.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: December 27, 2005
    Assignees: Merck & Co., Inc., Sharp Corporation
    Inventor: James M. Mundt
  • Adsorption powder containing cupric chloride
    Patent number: 6841513
    Abstract: An adsorption powder useful for the removal of mercury and other metals, as well as furans, dioxins and other organic compounds from gaseous streams. The powder may be characterized as containing a carbon-based powder and an effective amount of cupric chloride suitable for removing metals and organic compounds from high temperature and moisture gaseous streams. The powder may contain calcium hydroxide, sulfur, potassium permanganate, potassium iodide, and combinations thereof.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Youssef El-Shoubary, Rudy Maes
  • Orally active salts with tyrosine kinase activity
    Patent number: 6656942
    Abstract: The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: December 2, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Shyam B. Karki, Yuntae Kim
  • Tyrosine kinase inhibitors
    Patent number: 6586423
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley, Randall W. Hungate, Leonard Rodman
  • Inhibitors of prenyl-protein transferase
    Patent number: 6566385
    Abstract: The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: May 20, 2003
    Assignee: Merck & Co., Inc.
    Inventors: S. Jane deSolms, Gerald E. Stokker, Anthony W. Shaw
  • Preparation and isolation of indolocarbazole glycosides
    Patent number: 6559299
    Abstract: The present invention relates to a novel process to make indolocarbazole glycosides in high purity which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: May 6, 2003
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Steven Weissman, David Tschaen, Asayuki Kamatani, Shouichi Hiraga, Masashi Kawasaki, Takehiko Iida
  • Phase transfer catalyzed glycosidation of an indolocarbazole
    Patent number: 6555677
    Abstract: The present invention relates to a novel glycosidation process to make intermediates useful in the preparation of indolopyrrolocarbazole derivatives which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: April 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Daniel E. Petrillo, Steven A. Weissman, Shouichi Hiraga, Nobuya Satake, Kai Rossen
  • Tyrosine kinase inhibitors
    Patent number: 6544988
    Abstract: The present invention relates to pyrazolo-pyrimidinyl compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: April 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate
  • Inhibitors of prenyl-protein transferase
    Patent number: 6534506
    Abstract: The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: March 18, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Diem N. Nguyen, Craig A. Stump, Theresa M. Williams
  • Inhibitors of prenyl-protein transferase
    Patent number: 6525074
    Abstract: The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: February 25, 2003
    Assignee: Merck & Co., Inc.
    Inventors: S. Jane deSolms, Suzanne C. MacTough, Anthony W. Shaw
  • Tablet
    Patent number: D515202
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: February 14, 2006
    Assignee: Merck & Co., Inc
    Inventors: Tzyy-Show H. Chen, Craig B. Ikeda